Clinical Trial Search

Primary: The Percentage of Participants Who Did Not Stop Use When They Either Developed a New Symptom Referred to Anywhere in the Labeling or When Their Condition Worsened…

Primary: YMRS — 10; 18.82; 4.29 score on a scale

Primary: Geometric Mean Titers (GMTs) of Neutralizing Antibodies for Each of the 4 Dengue Serotypes at Day 120 in the Immunogenicity Subset — 5.3; 202.9; 293.8; 322.1 titer

Primary: Overall Survival — 5.78; 6.28 Months — p=0.6565

Primary: Annualized Relapse Rate (ARR) — 0.10; 0.25 number of relapses in a year — p=<0.001

Primary: First Event of Cardiovascular Death, Resuscitated Cardiac Arrest, Acute Myocardial Infarction, Stroke, or Urgent Hospitalization for Angina Requiring Coronary…

Primary: Percentage of Participants With Treatment-Emergent Adverse Events (TEAEs) — 100; 97.9; 14.7; 18.8 percent of participants

Primary: Annualized Relapse Rate (ARR) — 0.11; 0.22 number of relapses in a year — p=<0.001

Primary: Modified Fatigue Impact Scale (MFIS) Score — 40.6; 41.3; 39.0; 38.6 score on a scale

Primary: Percentage of Participants Who Achieved an American College of Rheumatology (ACR) 20 Response at Week 24 — 22.2; 52.0; 59.4 percentage of participants — p=< 0.001

Primary: Number of Participants With Freedom From Treatment Failure at 16-20 Weeks of Double Blind Therapy — 81; 43; 85 Participants — p=<0.001

Primary: Fageström Test for Nicotine Dependence Score at Baseline and After 90 Days of the Treatment — 6.53; 6.56; 5.96; 5.22 units on a scale

Primary: Change From Baseline in Asthma Quality of Life Questionnaire (AQLQ) Total Score — 0.715; 0.827; 0.753 Score on a scale — p=<0.001

Primary: Geometric Mean Concentration (GMC) of Anti-HBs at Day 196 for Lot-to-Lot Consistency (Per Protocol Set 1) — 5883.93; 4824.06; 5505.98 mIU/ml

Primary: Number of Participants Experiencing a Treatment Emergent Adverse Event (TEAE) — 8; 16; 0; 3 Participants